The presence of a graft-versus-tumor effect has been well established in leukemia but not in multiple myeloma. A 40-year-old patient with myeloma refractory to standard chemotherapy and autologous transplantation received a matched unrelated T-cell-depleted transplant after conditioning with fractionated total-body irradiation, thiotepa, and cyclophosphamide. This procedure resulted in a transient and incomplete response with evidence of rapidly progressive disease within 2.5 months posttransplantation. The RAFT-VERSUS-HOST disease (GVHD) is caused by recognition of host histocompatibility antigens by donor lymphocytes' and is probably triggered by a cytokine storm.' It was recognized early on in leukemic mice that allogeneic bone marrow grafts not only induced GVHD but also exerted antileukemic effects.' Evidence for the existence of a graft-versus-leukemia (GVL) and a graft-versuslymphoma effect in humans has been mainly indire~t.4.~ Direct evidence of a GVL effect in humans was first reported by Kolb et all0 and subsequently confirmed by others"-I3: infusion of donor buffy coat cells in patients with chronic myeloid leukemia (CML) relapsing after transplantation resulted in durable cytogenetic and molecular genetic remissions. However, complications ensued, including GVHD (go%), cytopenias (54%), and mortality (22%).14 Although a dissociation between the GVHD and the GVL effect has been described in m i~e , '~"~ these two entities have not yet been separated in humans.
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Herein, we report on a patient with refractory myeloma who was rapidly progressive after a T-cell-depleted matched unrelated donor transplant. She attained a complete remission, now lasting more than 14 months, after infusion of donor peripheral blood (PB) mononuclear cells. However, the procedure was complicated by severe acute and limited chronic GVHD. This observation proves the presence of a graft-versus-myeloma effect and the powerful antitumor effect mounted by a relatively low number of donor cells. of vincristine, melphalan, cyclophosphamide, and prednisone and two cycles of high-dose dexamethasone-pulse therapy (40 mg for 4 days on days 1 to 4, 9 to 12, and 17 to 20, and every 35 days) without response. Upon evaluation at our center in March 1993, bone marrow plasmacytosis was 75% with anaplastic features. Cytogenetic analysis showed a normal diploid karyotype. The peripheral hemogram showed a hemoglobin level of 8.8 g/dL, platelet count of 185 X lOY/L, and white blood cell count of 2.4 X 10'L. IgG was 8.2 g/dL, &microglobulin 2.7 mg/L, and M protein 5.8 g/dL; there was no Bence Jones proteinuria. A skeletal survey did not show lytic bone lesions. The patient progressed on interleukin-4 (5 pgkg for a total of 15 days) and vincristine, doxorubicin, and dexamethasone." In July 1993, high-dose cyclophosphamide (6 g/mz) and granulocyte/macrophage colony-stimulating factor were administered, yielding 4.3 X lo8 mononuclear cellskg. Because of persistent cytopenia (hemoglobin 9.2 g/dL, platelets 74 X loy& and leukocytes 109/L), a repeat bone marrow biopsy was performed that demonstrated a 90% cellularity with 90% plasma cells, indicating failure to respond to high-dose cyclophosphamide. Subsequent administration of melphalan 100 mg/m2 with interleukin-3, granulocytelmacrophage colony-stimulating factor, and peripheral stem-cell support resulted in a transient decline in M protein (decrease from 6.2 to 2.5 g/dL with subsequent increase to 4.3 g/dL) and reduction in marrow plasmacytosis to 40%. Because of the patient's young age, a marrow transplant from a matched unrelated donor was performed on December 16, 1993, after a conditioning regimen that consisted of hyperfractionated total-body irradiation 1,375 cGy, thiotepa 10 mgkg, cyclophosphamide 120 mgikg, and antithymocyte globulin 120 mgkg. T cells were removed from the marrow graft by a twostep soybean lectin-agglutination and sheep red blood cell-rosetting procedure. The number of T cells per kilogram infused was 0.04 X 105 by a limiting dilution assay and 0.14 X IO5 as measured by CD3 expression on flow cytometry. Methylprednisolone 2 mgkg was given posttransplantation from day +5 until day +19, with rapid tapering thereafter to decrease the probability of graft rejection. The patient showed prompt engraftment with an absolute neutrophil count of 0.5, 1.0, and 1.5 X 109/L on days +17, +IS, and +22. respectively.
Cytomegalovirus (CMV) reactivation (positive CMV antigen test) was documented on days +27 and +S7 posttransplantation. Serum M protein transiently decreased from 4.3 to 1.7 g/dL on day +21. with a subsequent increase to 3.4 g/dL on day +67. The bone marrow biopsy on day +35 showed a cellularity of 30% with trilineage engraftment but persistent plasmacytosis of 50%. On day +67, cellularity had increased further to 70% with 90% plasma cells and markedly decreased erythropoiesis and megakaryopoiesis. In the absence of clinical GVHD, previously cryopreserved donor peripheral buffy coat cells (original vol, 50 mL with lohikg white blood cells [WBC]) were administered on day +69 to induce an antitumor effect. However, neither GVHD nor tumor response were observed (Fig l ) .
On day + 1 16, fresh donor PB buffy coat cells from 1 0 0 mL donor blood were obtained, and 3.74 X 10' cells were infused. Phenotypic analysis showed the following cell counts: CD3, 1.2 X 1Oh/kg; CD4, 0.95 x 10h/kg; CD8, 0.24 x 106/kg; CD56, 0.24 X IOh/kg; and 
DISCUSSION
This patient's clinical course provides direct evidence that a graft-versus-myeloma effect exists. There was only a transient antitumor effect to total-body irradiation, thiotepa, and cyclophosphamide, and in fact progressive disease was clearly documented before day +70 posttransplantation. Cryopreserved donor PB cells had no apparent effect on myeloma parameters; fresh donor mononuclear cells obtained from 100 mL PB resulted in complete disappearance of all evidence of disease, based on morphology, flow cytometry to detect aneuploidy within the plasma cells with the same light-chain restriction as the myeloma cells," and M protein measurements in blood and urine on immunofixation. The lack of efficacy of cryopreserved donor cells might have been the consequence of excessive cell death during freezing and thawing or the presence of inadequate numbers of donor cells.
The antimyeloma effect in this patient was associated with severe GVHD requiring aggressive therapy with high-dose glucocorticosteroids and cyclosporin A without abrogation of the antitumor effect. The patient remains in complete remission 14 months after the fresh donor PB infusion with limited chronic GVHD and persistent mild thrombocytopenia (137 X 109/L).
It is extremely unlikely that the antitumor effect in this patient resulted from corticosteroid treatment for GVHD. The patient had been resistant to two cycles of high-dose dexamethasone before transplantation and remained in complete remission during 6 months of discontinuation of all steroid therapy after the donor cell infusion.
It is a humbling experience for BMT physicians to appreciate a profound antitumor effect exerted by donor PB cells after failure of myeloablative chemoradiotherapy. Our findings and recent results with donor buffy coat infusions in patients with relapsed CML strongly argue in favor of a major contribution of a graft-versus-tumor effect in the eradication of hematologic malignancies. In CML, donor buffy coat cells effect tumor cytoreduction exceeding 6 10gs.I~ Our findings appear to be different from those reported in CML in at least three aspects. Since the half-life of normal IgG is approximately 23 days," it can be assumed that the entire antitumor effect in our patient was accomplished within the first 2 weeks after donor cell infusion, which is in keeping with data in murine leukemia, in which the antileukemic effect of the allograft is attained within 6 to 7
and precedes the onset of severe GVHD.2"z5 Hence, a scenario can be envisioned whereby donor T cells are infused and subsequently eliminated after 14 to 21 days by exploiting the activation by ganciclovir of the previously transduced thymidine kinase suicide gene.2"
It is likely that future progress in cancer therapy will depend on judicious and safe manipulation of the immune system, rather than on further intensification of cytotoxic agents.
